Sage Therapeutics (BST:SG7) - Stock Price, News & Analysis

SG7 Stock Overview

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.

SG7 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 88.8% below our estimate of its fair value

Revenue is forecast to grow 44.21% per year

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Sage Therapeutics, Inc. Competitors

Formycon

XTRA:FYB

€701.1m

Biotest

XTRA:BIO3

€1.4b

MorphoSys

XTRA:MOR

€2.6b

Heidelberg Pharma

XTRA:HPHA

€141.2m

Price History & Performance

Summary of all time highs, changes and price drops for Sage Therapeutics
Historical stock prices
Current Share Price	US$14.67
52 Week High	US$47.40
52 Week Low	US$14.67
Beta	0.85
1 Month Change	-14.74%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-77.09%
5 Year Change	n/a
Change since IPO	-33.23%

Recent updates

Shareholder Returns

	SG7	DE Biotechs	DE Market
7D	0%	-0.2%	0.5%
1Y	n/a	-22.8%	1.3%

Return vs Industry: Insufficient data to determine how SG7 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how SG7 performed against the German Market.

Price Volatility

Is SG7's price volatile compared to industry and market?
SG7 volatility
SG7 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: SG7's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine SG7's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	487	Barry Greene	www.sagerx.com

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Parkinson’s diseases, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.

Sage Therapeutics, Inc. Fundamentals Summary

How do Sage Therapeutics's earnings and revenue compare to its market cap?
SG7 fundamental statistics
Market cap	€784.95m
Earnings (TTM)	-€469.33m
Revenue (TTM)	€84.94m

9.2x

P/S Ratio

-1.7x

P/E Ratio

Is SG7 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SG7 income statement (TTM)
Revenue	US$91.06m
Cost of Revenue	US$359.43m
Gross Profit	-US$268.37m
Other Expenses	US$234.77m
Earnings	-US$503.14m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-8.37
Gross Margin	-294.71%
Net Profit Margin	-552.52%
Debt/Equity Ratio	0%

How did SG7 perform over the long term?

See historical performance and comparison

SG7 Stock Overview

Rewards

Risk Analysis

Sage Therapeutics, Inc. Competitors

XTRA:FYB

€701.1m

XTRA:BIO3

€1.4b

XTRA:MOR

€2.6b

XTRA:HPHA

€141.2m

Price History & Performance

Recent News & Updates

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings released: US$1.80 loss per share (vs US$2.46 loss in 1Q 2023)

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Insufficient new directors

Insufficient new directors

Recent updates

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings released: US$1.80 loss per share (vs US$2.46 loss in 1Q 2023)

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Insufficient new directors

Insufficient new directors

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Insufficient new directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Second quarter 2023 earnings released: US$2.68 loss per share (vs US$2.13 loss in 2Q 2022)

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

Sage Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 Luminary Study of Sage-718 in Patients with Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease

Sage Therapeutics, Inc. Provides Business Update

Sage Therapeutics, Inc and Biogen Inc Announce Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints

Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology Congress

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

Third quarter 2021 earnings released: US$2.21 loss per share (vs US$2.03 loss in 3Q 2020)

President recently bought €861k worth of stock

Second quarter 2021 earnings released: US$1.83 loss per share (vs US$2.63 loss in 2Q 2020)

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 3000E Growth Index

Independent Chairman recently bought €825k worth of stock

Sage Therapeutics, Inc. and Biogen Inc. Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

Investor sentiment improved over the past week

Sage Therapeutics, Inc. to Host Sage Science Spotlight: SAGE-718 In Depth

First quarter 2021 earnings released: US$1.64 loss per share (vs US$2.44 loss in 1Q 2020)

Chief Operating Officer has left the company

Sage Therapeutics, Inc. Announces Continued Positive Zuranolone Data for Both 30 Mg and 50 Mg Doses in Open-Label SHORELINE Study in Patients with MDD

Sage Therapeutics, Inc. Announces Departure of Mike Cloonan as Chief Operating Officer, Effective May 3, 2021

Revenue beats expectations

Full year 2020 earnings released: EPS US$11.66 (vs US$13.38 loss in FY 2019)

Sage Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: €72.48

Sage Therapeutics, Inc. Appoints Barry Greene as President

Sage Therapeutics, Inc. Enters into A Collaboration and License Agreement with Biogen Ma Inc. and Biogen International Gmbh

Third quarter 2020 earnings released: US$2.03 loss per share

Revenue misses expectations

New 90-day high: €66.96

Sage Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high: €58.04